Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
Verona Pharma (Nasdaq: VRNA) will report its financial results for the second quarter and the first half of 2021 on August 5, 2021. The company plans to host a conference call at 8:30 a.m. EDT to discuss the results and provide a corporate update. Verona Pharma focuses on developing innovative therapies for respiratory diseases, with its leading candidate, ensifentrine, currently in Phase 3 trials for COPD. Ensifentrine aims to combine bronchodilator and anti-inflammatory properties in a single treatment.
- Ensifentrine potentially the first dual-action therapy for respiratory diseases.
- Currently in Phase 3 clinical trials for COPD maintenance treatment.
- None.
LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on Thursday, August 5, 2021 and host an investment community conference call at 8:30 a.m. EDT / 1:30 p.m. BST to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and reference conference ID 8333487:
- +1-888-317-6003 for callers in the United States
- +1-412-317-6061 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.
For further information please contact:
| Verona Pharma plc | US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200 |
| Victoria Stewart, Director of Investor Relations and Communications | info@veronapharma.com |
| Argot Partners (US Investor Enquiries) | Tel: +1-212-600-1902 verona@argotpartners.com |
| Kimberly Minarovich / Michael Barron | |
| Optimum Strategic Communications (International Media and European Investor Enquiries) | Tel: +44 (0)203 950 9144 verona@optimumcomms.com |
| Mary Clark / Karl Hard / Elakiya Rangarajah |
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
FAQ
When will Verona Pharma report its Q2 2021 earnings results?
What is Verona Pharma's leading product candidate?
What clinical phase is ensifentrine currently in for COPD?
What is the purpose of the conference call on August 5, 2021?
How can investors participate in the Verona Pharma conference call?
